The lesser-known ETF discussed in today’s article is already beating the market – up 185% year to date – and the author believes it will continue to produce strong gains going forward. More specifically, this ETF invests in companies that are at the forefront of genomics and helping to battle a wide range of diseases including sickle cell disease, cancer and even COVID-19. For more on this ETF and why the author believes now is the time for interested investors to get in, CLICK HERE.